BioSpace News Archive

Aclaris Therapeutics, Inc., a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, announced that management will present a company overview at the Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020 at 1:00 p.m. ET.

Precision BioSciences, Inc., a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform announced its participation in the following upcoming investor conferences

Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, announced today that its Chief Executive Officer, Dr. Roger Crystal, will present a company overview at the Jefferies Virtual Healthcare Conference

Erytech Pharma, a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, is announcing that its Combined Shareholders’ Meeting will be held in French in closed session at 2pm CEST on Friday, June 26, 2020, and also the associated details.

Nominates Three Medical Device Industry Veterans – Lonny Carpenter, David Floyd and James Hogan – for Election to the Board of Directors

Wave Life Sciences Ltd., a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to present virtually at the Jefferies 2020 Virtual Healthcare Conference on June 4, 2020 at 2:00 p.m. ET.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Jefferies Virtual Healthcare Conference at 11:00 a.m. ET on Tuesday, June 2, 2020. Kevin Gorman, Chief Executive Officer, will present at the conference.

Cumberland Pharmaceuticals Inc., a U.S. specialty pharmaceutical company, announces a new publication in Drugs - Real World Outcomes1, detailing the positive clinical outcomes with Vibativ® in treating patients with bacteremia or endocarditis.

Dicerna Pharmaceuticals, Inc., a leading developer of investigational ribonucleic acid interference therapeutics, announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present a corporate overview as part of the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020 at 4:30 p.m. ET.

Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will participate in two upcoming investor conferences